Advances on molecular mechanism of chronic inflammation-driven lung cancer induced by environmental carcinogens

Progress in Biochemistry and Biophysics

Volumn 41, Issue 1, 2014, Pages 41-51

  Lü, Jian Yi ^a   Zhang, Min ^a   Jin, Hong Lei ^a   Zhu, Jun Lan ^a   Wei, Jin Long ^a   Dai, Jia ^a   Huang, Hi Shan ^a   Gao, Ji Min ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Carcinogens; Inflammation; Lung cancer; Transformation

Indexed keywords

EID: 84899579021     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2013.00386     Document Type: Review

References (105)

1. Pass D P, Carbone D H, Johnson, et al. Principles and practice of lung cancer. 4th. Philadelphia, PA: Lippincott Williams & Wilkins, 2010: 287-324
2. Cheng S, Gao Y, Dong X, et al. Molecular and cytogenetic alterations in early stage of carcinogenesis of human lung. Cancer Lett, 2001, 162(Suppl): S5-S10
3. Vendramimi-Costa D B, Carvalho J E. Molecular link mechanisms between inflammtion and cancer. Curr Pharm Des, 2012, 18(26): 3831-3852
4. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society, 2011
5. World Health Organization website. Cancer: fact sheet no. 297 [EB/OL].2013-1 .http://www.who.int/mediacentre/factsheets/fs297/en
6. The Ministry of Health of the People's Republic of China. Third national retrospect pot-check of death-causation. 1st. Beijing: Peking Union Medical College Press, 2008: 22
7. Greenberg A K, Tsay J C. Chemoprevention of lung cancer: prospects and disappointments in human clinical trials. Cancers (Basel), 2013, 5(1): 131-148
8. De Marzo A M, Platz E A, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer, 2007, 7(4): 256-269 (Pubitemid 46486616)
9. Smerdová L, Ne a J, Svobodová J, et al. Inflammatory mediators accelerate metabolism of benzo [a] pyrene in rat alveolar type II cells: The role of enhanced cytochrome P450 1B1 expression. Toxicology, 2013, 314(1): 30-38
10. Ouyang W, Ma Q, Li J, et al. Benzo [a]pyrene diol-epoxide (B[a] PDE) upregulates COX-2 expression through MAPKs/AP-1 and IKKbeta/NF-kappaB in mouse epidermal C141 cells. Mol Carcinog, 2007, 46(1): 32-41 (Pubitemid 46095231)
11. Pan MG, Xiong Y, Chen F. NFAT gene family in inflammation and cancer. Curr Mol Med, 2013, 13(4): 543-54
12. Locksley R M, Killeen N, Lenardo M J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 2001, 104(4): 487-501 (Pubitemid 32201945)
13. Ouyang W, Hu Y, Li J, et al. Direct evidence for the critical role of NFAT3 in benzo[a]pyrene diol-epoxide-induced cell transformation through mediation of inflammatory cytokine TNF induction in mouse epidermal C141 cells. Carcinogenesis, 2007, 28(10): 2218-2226 (Pubitemid 47543384)
14. Tanaka H, Kijima H, Tokunaga T, et al. Frequent expression of inducible nitric oxide synthase in esophageal squamous cell carcinomas. Int J Oncol, 1999, 14(6): 1069-1073
15. Wilson K T. Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus. Dis Esophagus, 2002, 15 (1): 16-21 (Pubitemid 34811994)
16. Doll R. Report of the international committee on nickel carcinogenesis in man. Scand J Work Environ Health, 1990, 16(1 Spec No): 1-82
17. Denkhaus E, Salnikow K. Nickel essentiality, toxicity, and carcinogenicity. Critical Reviews in Oncology/Hematology, 2002, 42(1): 35-56 (Pubitemid 34229147)
18. Miao Y, Ouyang L, Zhou S, et al. Electrocatalysis and electroanalysis of nickel, its oxides, hydroxides and oxyhydroxides toward small molecules. Biosens Bioelectron, 2013, 53(10): 428-439
19. Salnikow K, Costa M. Epigenetic mechanisms of nickel carcinogenesis. J Environ Pathol Toxicol Oncol, 2000, 19 (3): 307-318
20. Semenza G L. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol, 2011, 76(10): 347-353
21. Garayoa M, Martínez A, Lee S, et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol, 2000, 14(6): 848-862 (Pubitemid 32260498)
22. Zhang D, Li J, Costa M, et al. JNK1 mediates degradation HIF-1 alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res, 2010, 70(2): 813-823
23. Ballif B A, Blettis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ, 2001, 12(8): 397-408 (Pubitemid 32762689)
24. Ligterink W, Hirt H. Mitogen-activated protein [MAP] kinase pathways in plants: versatile signaling tools. Int Rev Cytol, 2001, 201: 209-275 (Pubitemid 33717274)
25. Johnson G L, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 2002, 298(5600): 1911-1912 (Pubitemid 35425238)
26. Boucher M J, Morisset J, Vachon P H, et al. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem, 2000, 79(3): 355-369
27. Ding J, Huang Y, Ning B, et al. TNF-alpha induction by nickel compounds is specific through ERKs/AP-1-dependent pathway in human bronchial epithelial cells. Curr Cancer Drug Targets, 2009, 9(1): 81-90
28. Lu H, Shi X, Costa M, et al. Carcinogenic effect of nickel compounds. Mol Cell Biochem, 2005, 279(1-2): 45-67 (Pubitemid 43055143)
29. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl, 1987, 7: 1-440
30. Wang J P, Qi L, Moore M R, et al. A review of animal models for the study of arsenic carcinogenesis. Toxicol Lett, 2002, 133 (1): 17-31 (Pubitemid 34655542)
31. Pedlar R M, Ptashynski M D, Evans R, et al. Toxicological effects of dietary arsenic exposure in lake whitefish (Coregonus clupeaformis). Aquat Toxicol, 2002, 57(3): 167-189 (Pubitemid 34224869)
32. Lage C R, Nayak A, Kim C H. Arsenic ecotoxicology and innate immunity. Integr Comp Biol, 2006, 46(6): 1040-1054 (Pubitemid 44736438)
33. Bhattacharjee P, Banerjee M, Giri A K. Role of genomic instability in arsenic-induced carcinogenicity. Environ Int, 2013, 53(3): 29-40
34. Fang J, Nakamura H, Iyer A K. Tumor-targeted induction of oxystress for cancer therapy. J Drug Target, 2007, 15(7-8): 475-486 (Pubitemid 47213870)
35. Pi J, Horiguchi S, Sun Y, et al. A potential mechanism for the impairment of nitric oxide formation caused by prolonged oral exposure to arsenate in rabbits. Free Radic Biol Med, 2003, 35(1): 102-113 (Pubitemid 36782341)
36. Wijeweera J B, Gandolfi A J, Parrish A, et al. Sodium arsenite enhances AP-1 and NFkappaB DNA binding and induces stress protein expression in precision-cut rat lung slices. Toxicol Sci, 2001, 61(2): 283-294 (Pubitemid 32499396)
37. Brown M, Bellon M, Nicot C. Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood, 2007, 109(4): 1653-1659 (Pubitemid 46239600)
38. Habib G M. Arsenite causes down-regulation of Akt and c-Fos, cell cycle dysfunction and apoptosis in glutathione-deficient cells. J Cell Biochem, 2010, 110(2): 363-371
39. Eckert R L, Adhikary G, Young C A, et al. API transcription factors in epidermal differentiation and skin cancer. J Skin Cancer, 2013, 2013(5): 537028-537036
40. Huang C, Ma W Y, Li J, et al. Requirement of Erk, but not JNK, for arsenite- induced cell transformation. J Biol Chem, 1999, 274(21): 14595-14601
41. Huang C, Ma W Y, Li J, et al. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res, 2001, 21(1A): 261-267
42. Chen N Y, Ma W Y, Huang C, et al. Activation of PKC is required for arsenite-induced signal transduction. J Environ Pathol Toxicol Oncol, 2000, 19(3): 297-305
43. Ding J, Li J, Xue C, et al. Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells. J Biol Chem, 2006, 281(34): 24405-24413 (Pubitemid 44274213)
44. Huang C, Ke Q, Costa M, et al. Molecular mechanisms of arsenic carcinogenesis. Mol Cell Biochem, 2004, 255(1-2): 57-66 (Pubitemid 38159765)
45. Balkwill F, Mantovani A. Mantovani, Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255): 539-545 (Pubitemid 32173595)
46. Engels E A. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther, 2008, 8(4): 605-615 (Pubitemid 351818355)
47. Engels E A, Shen M, Chapman R S, et al. Tuberculosis and subsequent risk of lung cancer in Xuanwei, China. Int J Cancer, 2009, 124(5): 1183-1187
48. Pollard J W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer, 2004, 4(1): 71-78 (Pubitemid 38082155)
49. Hudson J D, Shoaibi M A, Maestro R, et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Experimental Medicine, 1999, 190(10): 1375-1382
50. Coussens L M, Werb Z. Inflammation and cancer. Nature, 2002, 420(6917): 860-867 (Pubitemid 36019639)
51. Nathan C. Points of control in inflammation. Nature, 2002, 420(6917): 846-852 (Pubitemid 36019637)
52. Verma G, Marella A, Shaquiquzzaman M, et al. Immunoinflammatory responses in gastrointestinal tract injury and recovery. Acta Biochim Pol, 2013, 60(2): 143-149
53. Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol, 2009, 86(5): 1065-1073
54. Witz I P. Yin-yang activities and vicious cycles in the tumor microenvironment. Cancer Res, 2008, 68(1): 9-13 (Pubitemid 351380098)
55. Macarthur M, Hold G L, El-Omar E M. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2004, 286(4): G515-G520 (Pubitemid 38374969)
56. Pal H C, Sharma S, Strickland L R, et al. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One, 2013, 8(10): e77270
57. Leek R D, Hunt N C, Landers R J, et al. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathology, 2000, 190(4): 430-436 (Pubitemid 30163582)
58. Grimshaw M J, Wilson J L, Balkwill F R. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol, 2002, 32(9): 2393-2400
59. Lin E Y, Pollard J W. Role of infiltrated leucocytes in tumour growth and spread. British J Cancer, 2004, 90(11): 2053-2058 (Pubitemid 38869704)
60. α kinase and enhances apoptosis induced by TNFα through downregulation of expression of nuclear factor κB-regulated gene products in human pancreatic cancer cells. PLoS One, 2013, 8(10): e77126
61. Jaiswal M, LaRusso N F, Burgart L J, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer research, 2000, 60(1): 184-190 (Pubitemid 30058750)
62. Rincón M, Flavell R A. Transcription mediated by NFAT is highly inducible in effector CD4+ T helper 2 (Th2) cells but not in Th1 cells. Mol Cell Biol, 1997, 17(3): 1522-1534 (Pubitemid 27097382)
63. Shaw J P, Utz P J, Durand D B, et al. Identification of a putative regulator of early T cell activation genes. Science, 1988, 241(4862): 202-205
64. Serfling E, Berberich-Siebelt F, Chuvpilo S, et al. The role of NF-AT transcription factors in T cell activation and differentiation. Biochim Biophys Acta, 2000, 1498(1): 1-18
65. Kiani A, Rao A, Aramburu J. Aramburu, manipulating immune responses with immunosuppressive agents that target NFAT. Immunity, 2000, 12(4): 359-372
66. Chen J, Amasaki Y, Kamogawa Y, et al. Role of NFATx (NFAT4/NFATc3) in expression of immunoregulatory genes in murine peripheral CD4+ T cells. J Immunology, 2003, 170 (6): 3109-3117 (Pubitemid 36302186)
67. 2+ mobilization and NFAT activation in primary mouse T cells. The Journal of Experimental Medicine, 2003, 197(11): 1525-1535
68. Yan Y, Li J, Ouyang W, et al. NFAT3 is specifically required for TNF-alpha-induced cyclooxygenase-2 (COX-2) expression and transformation of C141 cells. J Cell Sci, 2006, 119(Pt 14): 2985-2994 (Pubitemid 44177877)
69. Takai E, Tsukimoto M, Kojima S. TGF-β1 downregulates COX-2 expression leading to decrease of PGE2 production in human lung cancer A549 cells, which is involved in fibrotic response to TGF- β 1. PLoS One, 2013, 8(10): e76346
70. Abdullah M, Rani A A, Sudoyo A W, et al. Expression of NF-kB and COX2 in colorectal cancer among native indonesians: the role of inflammation in colorectal carcinogenesis. Acta Med Indones, 2013, 45(3): 187-192
71. Elzagheid A, Emaetig F, Alkikhia L, et al. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res, 2013, 33(8): 3137-3143
72. Wang D, Dubois R N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 2010, 29(6): 781-788
73. Buskens C J, Van Rees B P, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology, 2002, 122(7): 1800-1807 (Pubitemid 34651424)
74. Steele V E, Hawk E T, Viner J L, et al. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res, 2003, 523(3): 137-144 (Pubitemid 36293240)
75. Tak P P, Firestein G S, NF-kappaB: a key role in inflammatory diseases. J Clin Invest, 2001, 107(1): 7-11 (Pubitemid 32047405)
76. Gasparian A V, Yao Y J, Kowalczyk D, et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci, 2002, 115(Pt 1): 141-151 (Pubitemid 34105537)
77. Pikarsky E, Porat R M, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 2004, 431(7007): 461-466 (Pubitemid 39329586)
78. Gu X, Ke S, Liu D, et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem, 2006, 281(26): 17882-17889 (Pubitemid 44035587)
79. Prescott S M, Fitzpatrick F A. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta, 2000, 1470(2): M69-78 (Pubitemid 30155608)
80. Klein R D, Van Pelt C S, Sabichi A L, et al. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res, 2005, 65(5): 1808-1813 (Pubitemid 40478608)
81. Ivanov V N, Hei T K. Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells. Exp Cell Res, 2006, 312(8): 1401-1417
82. Perkins N D. The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci, 2000, 25(9): 434-440
83. Freed B M, Ouyang Y, McCue J M. Mechanisms of altered transcription by cigarette smoke. Toxicol Sci, 2001, 59(1): 1-2 (Pubitemid 32117975)
84. Deng J, Fujimoto J, Ye X F, et al. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila), 2010, 3(4): 424-437
85. κB signaling in inflammation and cancer. Mol Cancer, 2013, 12(8): 86-100
86. Huang Y, Davidson G, Li J, et al. Activation of nuclear factor-kappaB and not activator protein-1 in cellular response to nickel compounds. Environ Health Perspect, 2002, 110 (Suppl 5): 835-839 (Pubitemid 35276877)
87. Karin M, Greten F R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 2005, 5(10): 749-759 (Pubitemid 41400849)
88. Gorgoni B, Caivano M, Arizmendi C, et al. The transcription factor C/EBPbeta is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts. J Biol Chem, 2001, 276(44): 40769-40777
89. Hogan P G, Chen L, Nardone J, et al. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev, 2003, 17(18): 2205-2232 (Pubitemid 37128637)
90. Riedl K, Krysan K, Põld M, et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat, 2004, 7(3): 169-184 (Pubitemid 39024518)
91. Yoon J M, Lim J J, Yoo C G, et al. Adenovirus-uteroglobin suppresses COX-2 expression via inhibition of NF-kappaB activity in lung cancer cells. Lung Cancer, 2005, 48(2): 201-209
92. Fujimoto J, Toyoki H, Sakaguchi H, et al. Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer. Oncol Rep, 2006, 15(1): 21-25
93. Fakih M. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther, 2013, 13(4): 427-438
94. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. The EMBO J, 1996, 15(2): 290-298 (Pubitemid 26029207)
95. Garcí a-Román J, Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett, 2013, 335(2): 259-269
96. Bancroft C C, Chen Z, Yeh J, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, P13K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer, 2002, 99(4): 538-548 (Pubitemid 34461606)
97. Shih S C, Claffey K P. Role of AP-1 and HIF-1 transcription factors in TGF-beta activation of VEGF expression. Growth Factors, 2001, 19(1): 19-34 (Pubitemid 32970678)
98. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J National Cancer Institute, 2002, 94(11): 819-825 (Pubitemid 34705053)
99. Mattila M M, Ruohola J K, Karpanen T, et al. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. International J Cancer, 2002, 98(6): 946-951 (Pubitemid 34286696)
100. Karpanen T, Egeblad M, Karkkainen M J, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer research, 2001, 61(5): 1786-1790 (Pubitemid 32691984)
101. Karpanen T, Alitalo K. Lymphatic vessels as targets of tumor therapy. J Experimental Medicine, 2001, 194(6): F37-F42 (Pubitemid 32983007)
102. Fitzpatrick F A. Inflammation, carcinogenesis and cancer. International Immunopharmacology, 2001, 1(9): 1651-1667 (Pubitemid 32772637)
103. She J, Yang P, Hong Q, et al. Lung cancer in China: challenges and interventions. Chest, 2013, 143(4): 1117-1126
104. Choong N W, Salgia R, Vokes E E. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer, 2007, 8(Suppl 2): S52-60 (Pubitemid 46569718)
105. Cai T, Li X, Ding J, et al. A cross-talk between NFAT and NF-kappaB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells. Curr Cancer Drug Targets, 2011, 11(5): 548-559